InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,304.72
(
0.70%
)
US TECH 100
18,318.00
(
0.95%
)
Dow Jones
39,069.59
(
0.01%
)
Brent Oil
82.04
(
0.07%
)
Bitcoin
69,011.31
(
0.73%
)
Post# of 251941
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 829
Posts 119691
Boards Moderated 16
Alias Born 09/05/2002

DewDiligence

Member Level

Re: spongepaul post# 243965

Thursday, 09/29/2022 10:48:53 AM

Thursday, September 29, 2022 10:48:53 AM

Post# of 251941

OCUL—I am surprised by the drop in share price as I was very pleased with the results. 80% rescue free @six months is a success. Many thought 60% would be fantastic.

Investors appear to be skeptical that the data are enough of an improvement relative to monotherapy with high-dose Eylea (#msg-169896700). Moreover, it doesn’t help that regular-dose Eylea will soon have biosimilars.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up